PT - JOURNAL ARTICLE AU - Michael. J. Watson AU - Jonathon D. S. Holt AU - Scott J. O'Neill AU - Ke Wei AU - William Pendergast AU - Garrett J. Gross AU - Peter J. Gengo AU - Kwen-Jen Chang TI - ARD-353 [4-((2<em>R</em>,5<em>S</em>)-4-(<em>R</em>)-(4-Diethylcarbamoylphenyl)(3-hydroxyphenyl)methyl)-2,5-dimethylpiperazin-1-ylmethyl)benzoic Acid], A Novel Nonpeptide δ Receptor Agonist, Reduces Myocardial Infarct Size without Central Effects AID - 10.1124/jpet.105.092742 DP - 2006 Jan 01 TA - Journal of Pharmacology and Experimental Therapeutics PG - 423--430 VI - 316 IP - 1 4099 - http://jpet.aspetjournals.org/content/316/1/423.short 4100 - http://jpet.aspetjournals.org/content/316/1/423.full SO - J Pharmacol Exp Ther2006 Jan 01; 316 AB - A novel δ-receptor selective compound, ARD-353 [4-((2R,5S)-4-(R)-(4-diethylcarbamoylphenyl)(3-hydroxyphenyl)methyl)-2, 5-dimethylpiperazin-1-ylmethyl)benzoic acid], was evaluated for activity on infarct size in a rat model of acute myocardial infarction. ARD-353 was characterized as having δ receptor selectivity using radioligand binding and had no apparent selectivity between δ receptor subtypes as determined by [3H] cyclic [d-Pen2,d-Pen5]enkephalin (δ1) and [3H]Deltorphin II (δ2) competition binding. ARD-353 also showed selective δ receptor agonist activity in mouse-isolated vas deferens. There was no evidence of any seizure-like convulsions when ARD-353 was administered to mice either i.v. or p.o., implying minimal penetration of the blood-brain barrier. ARD-353 decreased infarct size in a left anterior descending coronary artery (LAD) occlusion model of myocardial infarction. In animals pretreated with ARD-353 (i.v.) and then subjected to 30 min of LAD occlusion followed by 90 min of reperfusion, infarct size was reduced in a dose-dependent manner compared with vehicle-treated controls. The effects of ARD-353 on infarct size were blocked by the δ1-opioid selective antagonist 7-benzylidenenaltrexone, indicating a significant role for the δ1-opioid receptor in the cardioprotective mechanism of ARD-353. ARD-353 (0.3 mg/kg i.v.) produced significant protection when administered 5 min and 12 and 48 h before ischemic insult or when given immediately after the ischemic insult (at the start of reperfusion). Given the lack of central nervous system effects and beneficial efficacy in the rat model of myocardial ischemia, it is felt that ARD-353 is the first nonpeptide δ-receptor agonist with true potential for clinical use before surgically induced ischemia or in an emergency setting. The American Society for Pharmacology and Experimental Therapeutics